asa guidelines for glp 1 drugs How should we approach patients on GLP-1 agonists? Check out this excellent editorial from Dr. Girish Joshi, "Clarifying the and Decoding the Enigma: Strategies Anesthetic Management of Patients on Glucagon-Like Perioperative Use of GLP-1 Receptor

doi: 10.1016/S0008-6363(02)00809-X

69 Whilst some studies have found that neither exogenously added nor secreted insulin has any autocrine signalling effect, this remains an area of controversy

Keywords: Glucagon, Glucagon-like peptide-1 receptor agonist, Glucose-dependent insulinotropic peptide receptor, Incretin, Obesity, Type 2 diabetes mellitus Introduction Type 2 diabetes mellitus (T2DM) and obesity are becoming more and more common worldwide, a phenomenon which greatly increases morbidity and mortality from conditions like cancer and heart disease, among many others [1]

Furthermore, another important motivator is the emphasis on weight management, with several GLP-1 agonists demonstrating weight loss benefits

They help you feel full sooner, reduce cravings, and promote healthier portion control

PF-06882961 is orally bioavailable and efficacious for lowering glucose and food intake in monkeys The pharmacokinetics of PF-06882961 were examined in rats and monkeys after intravenous (IV) and oral administration (Fig 5A, Table S7)